Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
On CNBC's "Mad Money Lightning Round," Jim Cramer said TORM plc (NASDAQ:TRMD) has a "remarkably high dividend yield. And as long as it has that dividend yield, the stock's going to stay up. But, when things start going bad, and they always do in this business, that yield's going to start going down."
在CNBC的 “瘋狂金錢閃電回合” 中，吉姆·克萊默說，TorM plc（納斯達克股票代碼：TRMD）的股息收益率非常高。而且，只要它有這樣的股息收益率，該股就會保持上漲。但是，當情況開始惡化時，而且這個行業一直如此，收益率就會開始下降。”
On July 23, Evercore ISI Group analyst Jonathan Chappell maintained TORM with an Outperform rating, while increasing the price target from $45 to $48.
7月23日，Evercore ISI集團分析師喬納森·查佩爾將TorM維持在跑贏大盤的評級，同時將目標股價從45美元上調至48美元。
Cramer recommended buying Trane Technologies plc (NYSE:TT). "Hard to stop a Trane," he added.
克萊默建議收購特靈科技有限公司（紐約證券交易所代碼：TT）。他補充說：“很難阻止特靈。”
Trane Technologies will report its second-quarter financial results on Wednesday, July 31. Analysts expect the company to report quarterly earnings at $3.08 per share, up from $2.68 per share in the year-ago period. Trane is projected to post quarterly revenue of $5.13 billion compared to $4.7 billion a year ago, according to data from Benzinga Pro.
特靈科技將於7月31日星期三公佈其第二季度財務業績。分析師預計，該公司公佈的季度收益爲每股3.08美元，高於去年同期的每股2.68美元。根據Benzinga Pro的數據，特靈預計將公佈51.3億美元的季度收入，而去年同期爲47億美元。
When asked about Axsome Therapeutics, Inc. (NASDAQ:AXSM), he said, "This is central nervous system, CNS. If you can make a breakthrough in CNS, your stock will double. If not, it will just go down. That's a double or nothing stock right there."
當被問及Axsome Therapeutics, Inc.（納斯達克股票代碼：AXSM）時，他說：“這是中樞神經系統，即中樞神經系統。如果你能在CNS方面取得突破，你的股票將翻一番。如果沒有，它只會下降。那是一隻要麼翻倍要麼全無的股票。”
On July 22, Needham analyst Ami Fadia initiated coverage on Axsome Therapeutics with a Buy rating and announced a price target of $130.
7月22日，Needham分析師阿米·法迪亞開始對Axsome Therapeutics進行報道，評級爲買入，並宣佈目標股價爲130美元。
The "Mad Money" host said SAP SE (NYSE:SAP) is "incredible" and recommended buying the stock. "I think that SAP is not done going higher," he added.
這位 “Mad Money” 主持人表示，SAP SE（紐約證券交易所代碼：SAP）“不可思議”，建議買入該股。他補充說：“我認爲SAP還沒有走高。”
On July 22, SAP reported second-quarter earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro.
7月22日，SAP公佈的第二季度每股收益爲82美分，未達到分析師普遍預期的每股1.19美元。根據Benzinga Pro的數據，季度銷售額爲89.2億美元，未達到分析師共識估計的89.6億美元，比去年同期的銷售額增長了8.81％。
Price Action:
價格走勢：
- Torm shares gained 2% to settle at $40.45 on Tuesday.
- Trane shares rose 2.3% to settle at $344.96.
- Sap rose 7.1% to close at $214.76 during Tuesday's session.
- Axsome Therapeutics shares fell 0.5% to settle at $85.66 on Tuesday.
- 週二，Torm股價上漲2％，收於40.45美元。
- 特靈股價上漲2.3％，收於344.96美元。
- 在週二的交易中，Sap上漲7.1％，收於214.76美元。
- 週二，Axsome Therapeutics股價下跌0.5％，收於85.66美元。
- Best Buy, Kroger And 2 Other Stocks Insiders Are Selling
- 百思買、克羅格和其他兩隻股票內部人士正在賣出